Across nearly 550,000 spine-surgery patients, being on a GLP-1 drug did not raise the odds of a single one of eight surgical complications the surgeons tracked. The one thing that did move was the bone itself: fusion worked better.
That comes from a systematic review and meta-analysis of 20 comparative studies, 546,668 patients in total, published online in the European Spine Journal ↗. The authors pooled every study they could find through December 2025 that compared spine-surgery outcomes in people taking a GLP-1 receptor agonist against people who were not.
The worry going in
Surgeons had a real reason to be nervous about operating on someone taking semaglutide or a similar drug. GLP-1 medications slow how fast the stomach empties. That is why anesthesia guidance now often tells patients to pause the drug before a procedure, because a full stomach under sedation raises the risk of breathing food into the lungs. Layer on the rapid weight loss and the muscle these drugs can strip along with fat, and the pre-surgical picture looked like it might mean more complications and slower healing.
The pooled numbers did not bear that out. Blood transfusions, operating time, length of hospital stay, surgical site infections, blood clots in the veins, hospital readmissions, repeat operations, and hardware failures all came out statistically indistinguishable between GLP-1 users and non-users. Every one of those confidence intervals crossed the line of no difference. For a class of drug that patients and surgeons were quietly worried about, a large null on the safety side is itself the headline.
The one that moved
Fusion is the point of most of these operations. The surgeon locks two or more vertebrae together with hardware and a bone graft and hopes the bone grows across the gap into one solid piece. When that fails, the hardware eventually loosens and the pain comes back, sometimes with another operation.
Here GLP-1 users fused better. The odds of a successful fusion were about half again higher (log odds ratio 0.42, 95 percent confidence interval 0.33 to 0.51, which works out to roughly 1.5-to-1). The effect held across every follow-up window the authors checked. That is the sentence worth arguing with, because the obvious mechanism is not obvious at all. Better blood-sugar control helps bone healing, and these drugs do that. But so does losing weight, and so does whatever separates people who get prescribed a GLP-1 drug and stay on it from people who do not. Observational data cannot tell those apart.
What it does and does not settle
This is Level III evidence, the authors are explicit about that. Every study in the pool was observational, so the analysis can show that GLP-1 use travels with better fusion and no extra complications, not that it causes either. Healthy-user bias is the standing objection to any result like this: people who fill and refill a prescription tend to be different from those who do not, in ways that also predict good surgical healing.
Still, the direction matters for a practical question thousands of patients face every month. The aspiration concern is about the hours around anesthesia and is handled by pausing the drug. The complication and fusion findings are about the weeks and months of recovery, and on that longer horizon this analysis found no penalty and a possible bonus. Prospective trials would have to confirm it before anyone changes practice.
Peptidemodel hosts cards for the two GLP-1 drugs at the center of this class, semaglutide ↗ and the dual GIP/GLP-1 agonist tirzepatide ↗, both built on the GLP-1 receptor ↗ target.